What were the key takeaways from Medifast's earnings call?

What guidance did Medifast's management provide for the next earnings period?

What is Medifast's latest dividend and current dividend yield?

What were the key takeaways from Medifast’s earnings call?

What is the market's earnings forecast for Medifast next quarter?

What factors drove the changes in Medifast's revenue and profit?

What does Medifast do and what are its main business segments?

What is Medifast's gross profit margin?

- **Strategic Transition**: CEO Dan Chard stepping down as CEO; Nick Johnson to lead metabolic health pivot. Q4 2025 marks first YoY increase in coach productivity (+6%), signaling recovery.
- **Clinical Differentiation**: 14% visceral fat reduction in clinical trials; new products targeting post-GLP-1 patients launching Q4 2026.
- **Financial Outlook**: 2026 revenue guidance $270M-$300M; loss per share $1.55-$2.75. Focus on cost discipline ($30M+ savings) and metabolic health innovation.

**【CEO Opening Remarks】**
- CEO Dan Chard announced his planned transition to Chairman effective June 1, 2026, with Nick Johnson succeeding as CEO. Chard emphasized the company's strategic pivot to metabolic health, driven by the rise of GLP-1 medications and shifting consumer demand.
- Highlighted clinical results of the metabolic synchronization approach: 14% reduction in visceral fat while preserving 98% lean mass in a 16-week study. This forms the basis for a new product line targeting metabolic health.
- Noted early signs of recovery: Q4 2025 coach productivity increased 6% YoY, the first positive growth since Q2 2022. Active earning coaches declined 40.6% YoY to 16,100, but revenue per coach rose 6.2% to $4,664.

**【President (CEO-elect) Commentary】**
- Nick Johnson highlighted the coach-led model's strength, with clients achieving 10x more weight loss and 17x more fat loss when guided by coaches. The new Premier+ and EDGE programs aim to simplify client acquisition and retention.
- Q4 2025 saw 16% of active coaches reach the Executive Director rank, the highest since Q2 2023, with 90% retention in the following 2 months. Coach-led meetings increased significantly in Q4, signaling renewed field engagement.
- Focused on repositioning the business to target the metabolic health market, with a younger, more productive coach base expected to drive future growth.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $75.1M (-36.9% YoY), driven by 40.6% YoY decline in active earning coaches. Loss per share: $1.65 (including $1.10 from non-cash tax valuation allowance).
- Gross profit: $52.1M (-40.9% YoY), margin 69.4% (down 470bps). SG&A: $59.9M (-31.5% YoY), benefiting from $18.6M reduction in coach compensation and $5.8M in marketing cuts.
- 2026 guidance: Revenue $270M-$300M, loss per share $1.55-$2.75. Anticipates Q4 2026 launch of new metabolic health products to drive profitability improvements.

**【Q&A Highlights】**
- **Coach Productivity Sequencing**: CEO Chard noted Q4 2025 productivity growth (6% YoY) as a leading indicator, with potential for revenue growth in 2026. CFO Maloney expects gradual improvement, with Q4 2026 as a key inflection point with new product launches.
- **Consumer Base Shift**: 25% of clients have used or are on GLP-1 medications. New products focus on visceral fat reduction and lean mass preservation, appealing to post-GLP-1 users who regain weight.
- **Field Dynamics**: Younger, more productive coaches (average tenure <2 years) now represent 60% of active coaches, replacing less productive tenured coaches. This mix shift is expected to drive higher sponsorship and retention rates.


Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript

- **Strategic Shift to Metabolic Health**: Medifast is transitioning to a science-backed metabolic health solution, targeting visceral fat reduction (14% at 16 weeks) while preserving lean mass, complementing GLP-1 medications' limitations.
- **Coach-Centric Growth**: The EDGE program scales high-productivity coaches (average $6,000 revenue), with 61% of coaches supporting GLP-1 users and 22% of clients reporting GLP-1 usage.
- **Product Innovation**: A new 2026 product line using metabolic synchronization science will replace the Essential line, with initial coach feedback positive.
- **Financial Challenges**: Q3 2025 revenue down 36.2% YoY to $89.4 million, with gross margin at 69.5% (-590 bps YoY). Q4 guidance projects $65-70 million revenue and EPS loss $0.70-$1.25.
- **Economic Resilience**: Despite broader economic softness, clients prioritize health spending, with high retention rates and 22% GLP-1 client overlap.


**【Management Opening Remarks】**
- Steven Zenker introduced the call, emphasizing the company's strategic focus on metabolic health and the importance of the earnings release. He highlighted the risks of forward-looking statements and reminded investors of the webcast replay availability.

**【CEO Commentary】**
- **Strategic Shift to Metabolic Health**: CEO Daniel Chard outlined the company's transition from a weight loss focus to a comprehensive metabolic health solution. The program targets visceral fat reduction (14% at 16 weeks) while preserving lean mass (98% retention), complementing GLP-1 medications' limitations.
- **Coach-Centric Model**: 61% of coaches have worked with GLP-1 users, and 22% of clients report GLP-1 usage. Coaches drive 10x more weight loss and 17x more fat loss than self-directed clients. The EDGE leadership program aims to scale high-productivity coaches (average $6,000 revenue per coach).
- **Product Innovation**: A new product line using metabolic synchronization science will replace the Essential product line in 2026, with initial coach feedback positive.
- **Financial Highlights**: Q3 2025 revenue of $89.4 million (-36.2% YoY), EPS within guidance, and 19,500 active coaches (-35% YoY). Coach productivity stabilized at $4,585 (-1.9% YoY).

**【CFO Financial Commentary】**
- **Revenue Decline**: $89.4 million (-36.2% YoY) due to 35% active coach decline. Gross profit margin dropped to 69.5% (-590 bps YoY) due to fixed cost leverage loss and a $1.5 million Essential product reformulation charge.
- **Cost Management**: SG&A decreased 36% YoY to $66.2 million, driven by 35% coach reduction and $19.7 million lower compensation. The company maintains $173.5 million in cash with no debt.
- **Q4 Guidance**: Revenue $65-70 million, EPS loss $0.70-$1.25, reflecting ongoing stabilization efforts.

**【Q&A Highlights】**
- **Strategy Implementation**: Coaches are being trained on metabolic health science through leadership retreats, with EDGE program scaling high-productivity coaches.
- **Economic Impact**: Despite broader economic softness, clients prioritize health spending, evidenced by high retention rates and 22% GLP-1 client overlap.
- **Financial Alignment**: SG&A decline aligns with revenue, with 2024 one-time expenses (LifeMD collaboration) no longer recurring. Margins expected to improve with coach productivity recovery.


Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript

- **Metabolic Health Focus**: Medifast programs preserve lean mass (98% retention in study), targeting post-GLP-1 users. ASCEND and ACTIVE lines meet demand for maintenance and active lifestyles.
- **Coach Growth Challenges**: 33% YoY decline in active coaches, but new coaches show strong productivity. EDGE program aims to reignite growth through simplified incentives and training.
- **Financial Resilience**: Q2 net income $2.5M (up from loss), despite 37.4% revenue drop. Strong cash position ($162.7M) supports strategic initiatives.
- **Market Strategy Shift**: Reduced company-led marketing, focusing on coach-driven acquisition and SEO to align with evolving client needs.

**【CEO Summary Section】**
- **Strategic Focus on Metabolic Health**: Emphasized the role of Medifast programs in preserving lean mass during weight loss, with a clinical study showing 98% lean mass retention. Highlighted the growing need for long-term solutions post GLP-1 medication use.
- **New Pricing Model**: Introduced the Premier+ auto-ship program to simplify client pricing and coach compensation, aiming to reduce churn and improve predictability.
- **Coach Support Initiatives**: Launched the EDGE program to streamline onboarding, provide incentives, and enhance leadership development for coaches. New app features offer data insights for client tracking and business growth.
- **Product Line Expansion**: Rolled out ASCEND (for GLP-1 users and maintenance phase) and ACTIVE (for active individuals), with ASCEND meeting sales expectations.
- **Coach Performance**: Despite a 33% YoY decline in active coaches, new coach productivity remained strong, with sequential improvement in average revenue per coach.

**【CFO Financial Commentary】**
- **Q2 Financials**: Revenue $105.6M (-37.4% YoY), driven by 32.7% drop in active coaches. Gross profit margin 72.6% (-10 bps YoY). SG&A expenses down 40.8% to $77.7M due to fewer coaches and no promotions. Net income $2.5M ($0.22 EPS), up from -$8.2M YoY, aided by a $2.6M gain on LifeMD stock sale.
- **Balance Sheet**: $162.7M cash, no debt. Guidance for Q3: Revenue $70-90M, EPS -$0.60 to $0.00, reflecting cautious outlook amid pricing changes.

**【Q&A Highlights】**
- **Coach Adaptation**: 60% of coaches have supported GLP-1 clients, 23% used GLP-1 themselves. New coaches are GLP-1 savvy, with training focused on metabolic health and GLP-1 transitions.
- **ASCEND Performance**: Meeting expectations, used by clients on GLP-1 and transitioning to maintenance. ACTIVE line targets active individuals needing muscle support.
- **Marketing Strategy**: Limited company-led ads (SEO, strategic campaigns), prioritizing coach-driven acquisition through personal stories.


Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript

- **Coach Recruitment Recovery**: First meaningful YoY increase in new coaches (double-digit growth), signaling potential turnaround.
- **GLP-1 Integration Success**: 50% of coaches now support GLP-1 clients, with 25% having personal experience, enhancing program relevance.
- **Product Line Expansion**: ASCEND line captures 15% of orders, addressing weight maintenance needs post-GLP-1 use.
- **Financial Resilience**: $164.6M cash on hand supports strategic initiatives despite Q1 net loss of $0.8M.
- **Q2 Outlook**: Expected YoY decline acceleration due to absence of Q1 promotions, but management sees 2025 as turnaround year.

**【CEO Summary Section】**
- Medifast reported Q1 2025 revenue of $115.7 million, down 33.8% YoY, driven by a 32.8% decline in active earning OPTAVIA coaches to 25,400. However, new coach recruitment saw a double-digit YoY increase, the first meaningful growth in three years.
- Management emphasized the importance of the OPTAVIA program in addressing the limitations of GLP-1 medications, such as muscle mass loss and high discontinuation rates (74% within 12 months). Coaches now have tools to support clients on, off, or without GLP-1 drugs.
- Key initiatives include: 
  1. Streamlined coach development paths with clearer success metrics.
  2. Enhanced digital tools for tracking client progress and personalized plans.
  3. Expanded product lines (e.g., ASCEND for weight maintenance, ACTIVE for exercise integration).
- 50% of coaches have supported GLP-1 clients, with 25% having personal experience using the drugs.

**【CFO Financial Commentary】**
- Gross profit declined 33.8% to $84.2 million, but margin remained stable at 72.8%. SG&A expenses fell 28.4% to $85.5 million, driven by lower coach compensation and reduced marketing costs.
- Net loss was $0.8 million ($0.07 per share), compared to net income of $8.3 million ($0.76 per share) in Q1 2024. The company maintained strong cash reserves of $164.6 million with no debt.
- Q2 2025 guidance: Revenue $85-105 million, loss per share $0-0.55. Management expects Q2 to be the low point for YoY declines, with potential improvement in coach productivity by end-2025.

**【Q&A Highlights】**
- **New Coach Productivity**: New cohorts exhibit YoY growth in client acquisition, similar to pre-pandemic levels. Incentives for early wins and leadership development are driving this trend.
- **ASCEND Line Performance**: ASCEND orders represented ~15% of total in Q1, aligning with expectations. The line helps preserve muscle mass for GLP-1 users.
- **GLP-1 Impact on Coaches**: 50% of coaches have supported GLP-1 clients, reducing controversy and increasing program relevance. Coaches view GLP-1 as a tool, not a solution, aligning with OPTAVIA's holistic approach.
- **Cost Strategy**: Company-led marketing will remain limited, with focus on coach-driven growth. This shift reflects higher ROI in coach support vs. broad marketing.


Medifast (MED)-28 Apr 25-2025 Q1 Earnings call transcript

- **GLP-1 market leadership**: 17% of Q1 orders include new ASCEND line targeting GLP-1 users, with 44% of coaches now supporting medication users.
- **Stabilizing trends**: Coach productivity improved sequentially (-5.5% YoY in Q4 vs. -22.2% in Q1), signaling potential 2025 turnaround.
- **Financial resilience**: $162M cash balance, $21M cost savings in 2024, and 2025 guidance for early productivity metrics improvement.
- **Growth catalysts**: 2025 focus on reactivated customers (CAC efficiency), clinical research on GLP-1 outcomes, and women's health expansion.

**【CEO Strategic Overview】**
- Medifast is adapting to the GLP-1 weight loss medication market by integrating solutions for customers on, off, or avoiding medications. The new OPTAVIA ASCEND line targets muscle preservation and long-term weight management, with 17% of Q1 orders including ASCEND products.
- Coach productivity (revenue per active earning coach) improved sequentially, down 5.5% YoY in Q4 vs. 22.2% in Q1, driven by 44% of coaches supporting GLP-1 users (vs. 12% in 2023). Customer mix shifted to 17% with prior GLP-1 use (vs. 3% in 2023).
- 2025 priorities include accelerating customer acquisition through company-led marketing and coach training, advancing clinical research on GLP-1 outcomes, and expanding into women's health categories.

**【CFO Financial Highlights】**
- Q4 2024 revenue: $119M (-37.7% YoY) due to 34.1% decline in active earning coaches and lower productivity. Non-GAAP EPS: $0.10 (above guidance).
- Gross margin improved 10bps to 74.1%, offset by 400bps increase in SG&A as a % of revenue due to $24M company-led marketing spend.
- Fuel for the Future initiative delivered $21M cost savings in 2024, with $15-20M expected in 2025. Cash balance: $162.3M (no debt).
- Q1 2025 guidance: Revenue $100-120M (-37% YoY midpoint), EPS loss $0.00-$0.50. Expect 2025 to show early signs of stabilization in coach productivity metrics.

**【Q&A Key Takeaways】**
- Marketing efficiency: 2024 spent $24M on company-led marketing, but 2025 will optimize spend by focusing on reactivating lapsed customers (lower CAC) and scaling proven coach practices. Coach compensation remains the largest marketing driver (~80% of customer acquisition).
- Coach dynamics: 44% of coaches now support GLP-1 users, but active earning coach count will remain pressured until productivity metrics (revenue per coach) turn positive YoY in 2025.
- ASCEND adoption: 17% of Q1 orders included ASCEND, with strong feedback from coaches on its ability to engage GLP-1 users. ASCEND's focus on muscle preservation addresses a gap in the GLP-1 market (up to 74% of patients regain weight post-treatment).

Actual												1.93	1.96	2.91	2.34	3.46	3.96	3.56	2.91	3.59	3.87	3.32	3.7	3.67	2.77	2.12	1.09	0.66	0.92	0.35	0.1	-0.0335	0.4008	-0.21	-0.55
Forecast												1.3267	1.8325	2.4575	2.378	2.7267	3.3167	3.08	2.6533	3.57	3.275	1.91	2.2159	2.4	1.44	1.065	0.9622	0.8024	0.3886	-0.19	-0.15	-0.25	-0.19	-0.36	-0.82
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+45.47%	+6.96%	+18.41%	-1.60%	+26.89%	+19.40%	+15.58%	+9.67%	+0.56%	+18.17%	+73.82%	+66.98%	+52.92%	+92.36%	+99.06%	+13.28%	-17.75%	+136.75%	+284.21%	+166.67%	+86.60%	+310.95%	+41.67%	+32.93%

MED

MED fundamentals

MED Q4 2025 Earnings

Earnings Call

You can ask Aime

MED

MED fundamentals

MED Q4 2025 Earnings

Earnings Call

MED Earnings Call Summary for Q4/20254:30 PM on Feb 17, 2026

MED Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

MED Earnings Call Summary for Q2/20254:30 PM on Aug 4, 2025

MED Earnings Call Summary for Q1/20254:30 PM on Apr 28, 2025

MED Earnings Call Summary for Q4/20244:30 PM on Feb 18, 2025

You can ask Aime